Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …

Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [5] It is a bispecific T-cell engager that binds delta-like ligand …

Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells.

Feb 1, 2026 · Tarlatamab-dlle injection is used to treat extensive stage small cell lung cancer (ES-SCLC), which is cancer that has spread throughout the lung or to other parts of the body in patients …

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC)...

One promising BiTE is tarlatamab, also known as AMG 757 (9). This drug works by binding to delta-like ligand 3 (DLL3) on tumor cells and cluster of differentiation 3 (CD3) on T cells, which triggers T cell …

Nov 20, 2025 · The FDA has granted full approval to tarlatamab, a targeted immunotherapy drug for treating adults with advanced small cell lung cancer (SCLC) that that has spread after platinum …

May 16, 2024 · IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum …

Tarlatamab-dlle is in a class of medications called bispecific T-cell engager antibodies. It works by slowing or stopping the growth of cancer cells in your body.

Tarlatamab is a bispecific T-cell engager immunotherapy directed to cancer cells expressing delta-like ligand 3 (DLL3). DLL3 is a protein and inhibits Notch signaling, which is abnormally expressed on the …